[ad_1] SAN FRANCISCO, Dec. 7, 2025 /PRNewswire/ — Prologis, Inc. (NYSE: PLD) announced today that Prologis, L.P. will redeem all of its outstanding 3.00% Notes due June 2, 2026 (CUSIP Number 74340XBB6, ISIN XS1072516690 and […]
Tag: Inc.
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
[ad_1] R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion […]
HALLMARK PRESENTS A DISNEY LOVE STORY
[ad_1] TWO ICONIC BRANDS TEAM UP TO CREATE AN UNFORGETTABLE HOLIDAY ADVENTURE LACEY CHABERT AND TRAVIS VAN WINKLE FIND UNEXPECTED MAGIC AND ROMANCE IN HOLIDAY EVER AFTER: A DISNEY WORLD WISH COME TRUE DEBUTING IN […]
Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
[ad_1] HONG KONG, Dec. 7, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the successful inclusion of all five of the Company’s self-developed innovative drugs into the updated National Reimbursement Drug List […]
Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
[ad_1] LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in […]
